Kyowa partners KW-6356 with Lundbeck

Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) granted H. Lundbeck A/S (CSE:LUN) exclusive rights outside of Asia to develop and commercialize KW-6356. The adenosine A2A receptor (ADORA2A) antagonist is in preclinical testing to treat Parkinson's disease. Lundbeck also has the right to select back-up compounds. ...